20 August 2020
ANDHealth, Australia’s leading organisation in accelerating the commercialisation of evidence-based digital health technologies, today announced new outcomes achieved by the Australian companies which participated in the two-year pilot of the ANDHealth+ Program.
The companies report quarterly against key growth metrics. In the June quarter these outcomes included:
But of greatest interest is the significant growth experienced by these companies since January, at the same time as many other sectors and companies suffered catastrophic losses and staff redundancies during the COVID-19 crisis.
Demonstrating both the growth potential of this nascent industry, and also its ability to support the health of Australians during significant disruption to the health system, during the first half the cohorts reported increases of:
ANDHealth founder and CEO Bronwyn Le Grice said: “These figures clearly demonstrate that Australian digital health companies are capable of delivering outcomes that are internationally competitive and which demonstrate extraordinary impact.
“We believe that there is a clear case for Australian governments to step in and support this nascent, high-potential industry to achieve the triple aim of economic growth, health system resilience and better healthcare, and growth of advanced manufacturing capabilities.”
The ANDHealth+ cohort companies are DoseMe, CancerAid, Perx, Atmo, Vitalic, Seer Medical, AllergyPal, Health Delivered and Kesem Health. They were selected to take part in the ANDHealth+ program from more than 150 applicants, and were then screened by a multi-sector, C-suite member panel.
The companies then participated in a globally unique deep industry immersion and advisory program which delivered tailored support and advice specific to their needs and business strategy. Unlike other programs, ANDHealth+ is not curriculum-based but involves a tailored, multi-disciplinary, multi-sector panel of C-suite executives advising and supporting the company across all aspects of its business for up to nine months.